To investigate the role of liver-specific expression of glucokinase (GCK) in the pathogenesis of hyperglycemia and to identify candidate genes involved in mechanisms of the onset and progression of maturity onset diabetes of the young, type 2 (MODY-2), we examined changes in biochemical parameters and gene expression in GCK knockout (gck w/-) and wild-type (gck w/w ) mice as they aged. Fasting blood glucose levels were found to be significantly higher in the gck w/-mice, compared to age-matched gck w/w mice, at all ages (P b 0.05), except at 2 weeks. GCK activity of gck w/-mice was about 50% of that of wild type (gck w/w ) mice (P b 0.05). Glycogen content at 4 and 40 weeks of age was lower in gck w/-mice compared to gck w/w mice. Differentially expressed genes in the livers of 2 and 26 week-old liver-specific GCK knockout (gck w/-) mice were identified by suppression subtractive hybridization (SSH), which resulted in the identification of phosphoenolpyruvatecarboxykinase (PEPCK, also called PCK1) and Sterol O-acyltransferase 2 (SOAT2) as candidate genes involved in pathogenesis. The expressions of PEPCK and SOAT2 along with glycogen phosphorylase (GP) and glycogen synthase (GS) were then examined in GCK knockout (gck w/-) and wild-type (gck w/w ) mice at different ages. Changes in PEPCK mRNA levels were confirmed by real-time RT-PCR, while no differences in the levels of expression of SOAT2 or GS were observed in age-matched GCK knockout (gck w/-) and wild-type (gck w/w ) mice. GP mRNA levels were decreased in 40-week old gck w/-mice compared to age-matched gck w/w mice. Changes in gluconeogenesis, delayed development of GCK and impaired hepatic glycogen synthesis in the liver potentially lead to the onset and progression of MODY2.
GCK plays an essential role in blood glucose homeostasis and, in humans, mutations in the GCK gene cause MODY-2 (Froguel et al., 1992; Velho et al., 1992) , a disease that is characterized by an early onset and persistent hyperglycemia. GCK is a member of the family of hexokinases that phosphorylate glucose into glucose-6-phosphate as the first step in glycolysis (Printz et al., 1993) . There are two isoforms of GCK, namely, the β-cell-specific and liver-specific isoforms, each of which is characterized by an isoform-specific first exon (Iynedjian et al., 1989; Magnuson, 1990) . In β-cells, GCK plays a critical role in glucose-responsive insulin secretion by functioning as a 'glucose sensor', where the enzymatic kinetics of GCK allows β-cells to change the glucose phosphorylation rate over the physiological range of glucose concentrations (Matschinsky, 2002) .
In the liver, GCK is thought to determine the rates of both glucose uptake and glycogen synthesis (Magnuson et al., 1989; Velho et al., 1996) . The role of the liver in the pathogenesis of hyperglycemia that characterizes MODY-2 has not yet been clearly resolved. Characterization of the cell-specific roles of GCK in glucose homeostasis requires animal models where the enzyme is selectively eliminated in specific sites without affecting expression at other sites. We generated a hepatocyte-specific gene knockout of the glucokinase gene in mice (Zhang et al., 2004 ) using a Cre-loxP gene targeting strategy to identify tissue-specific alterations in glucose metabolism that contribute to pathogenesis. The liver-specific knockout mouse, thus, is an ideal animal model to investigate the liver cell-specific roles of GCK in glucose homeostasis and its role in MODY2. In a previous study, our GCK knockout mice were shown to have increased blood glucose levels at 4 weeks, and at 6 weeks had both fasting blood glucose levels that were significantly higher than in gck w/w mice and displayed impaired glucose tolerance (Zhang et al., 2004 ). Here we further characterize these liver-specific gck w/-mice by examining their body weight, fasting blood glucose, intraperitoneal glucose tolerance test (IPGTT), fasting serum insulin, total cholesterol (TC), triglyceride (TG) and GCK activity in comparison to those of gck w/w mice out to 26 weeks of age. To investigate the reasons for the increases in blood glucose levels from 4 weeks of age and as a first step to identify genes that may lead to the onset and development of MODY2, we used a suppression subtractive hybridization (SSH) screen to identify genes that are differentially expressed in the livers of liver-specific gck w/-mice at the ages of 2 and 26 weeks and characterized the expression pattern of two identified candidate genes at different ages in gck w/-and gck w/w mice.
Material and methods

Animals
Liver-specific heterozygous gck w/-mice at 2, 4, 16, 26 and 40 weeks of age and age-matched gck w/w mice, as control animals, were used in this study. All mice had a C57BL/6J background. The liver specific gck w/-mice was previously constructed by our lab (Zhang et al., 2004) . All animal experiments were conducted in accordance to the "Guidelines for Animal Experiment" and were approved by the Animal Care Committee of the Peking University Health Science Center.
Biochemical analysis
Body weight was measured in all mice. IPGTT was performed in each group by intraperitoneal injection of a 20% glucose solution at a dose of 2 g kg −1
. Animals were tested at 3:00 p.m. after an 8-h fast. Blood glucose concentrations after an 8 h fast were measured from the tails of mice with a Roche blood glucose monitor (Glucotrend 2). Fasting Serum insulin levels were determined by radioimmunoassay (RIA) using a human insulin RIA kit. Triglyceride and total cholesterol were determined using commercial kits that employ an enzymatic method (ChangChang, China) and an automatic analyzer (AMS-18C). Glycogen content was determined using a Kit (NanJingJiancheng Company, China) according to the manual provided by the manufacturer.
Liver GCK activity was measured using methods that have previously been described (Rencurel et al., 1998) . Livers were isolated and homogenized in 3 volumes of ice cold 20 mM KH 2 PO 4 -KOH (pH 7.0) containing 100 mM KCl, 1 mM MgCl 2 , 1 mM EDTA, 5% (v/v) glycerol, 1 mg/ml BSA and 1 mM DTT. Homogenates were centrifuged at 160 ×g for 30 min and then the supernatants were ultracentrifuged for 60 min at 100,000 ×g. Supernatants were incubated for 30 min at 37°C with 50 mM HEPES-NaOH, 100 mM KCl, 8 mM MgCl 2 , 0.5 mM NAD, 1 mM DTT, 1 U/ml G6PDH, 5 mM ATP and 50 mM or 0.5 mM glucose. GCK activity was corrected by subtracting the activity measured at 0.5 mM glucose from the activity measured at 50 mM glucose. Protein concentrations were determined with the Bio-Rad protein assay reagent (Bradford, 1976) .
Western blotting analysis of GCK levels
Liver was homogenized in a buffer containing 50 mM TrisHCl (pH 8.0), 150 mM NaCl, 0.02% NaN3, 1% SDS, 1 mM EDTA, 0.5% Sodium deoxycholate, 100 mg/ml PMSF, 1 mg/ml leupeptin and 1% NP-40. Sixty micrograms of protein was analyzed in Western blot experiments with either an anti-GCK antibody (Santa Cruz Biotechnology, Inc., CA; dilution 1:200) or an anti-β-actin antibody (1:1000). Images were generated and quantified by ChemiDocXRS (Bio-Rad, USA).
Suppression subtractive hybridization (SSH)
SSH were performed with RNA isolated from the livers of 2-week and 26-week old gck w/-mice in both directions to identify transcripts that are both up-and down-regulated. To find genes that are overexpressed in 26-week-old gck w/-mice, RNA from these mice was used as the "tester," while the 2 week-old gck w/-mice RNA was used as the "driver." For the reverse subtraction analysis, the "tester" and "driver" mice were switched. Liver total RNA was extracted with TRIZOL (Invitrogen). PolyA + mRNA was isolated using the Oligotex mRNA Midi Kit (Qiagen) and converted to double-stranded cDNA using a cDNA synthesize kit (Takara). Tester and driver cDNAs were digested with RsaI (Promega). SSH was performed as the manufacturer of PCR-SELECT cDNA Subtraction Kit (Clontech). PCR reaction products generated by SSH were shotgun ligated into the pMD-18 T vector (Takara), transformed into JM109 cells, and plated onto Luria-Bertani (LB) agar plates containing ampicillin (100 μg/ml). Recombinant colonies were picked from the plates and sequenced by Invitrogen. The identity of the clone sequences was determined by BLAST searches against the mouse genome.
Quantification of mRNA by real-time quantitative PCR
Total liver RNA was extracted using Trizol. High-Capacity cDNA Reverse Transcription kits (Applied Biosystems) were used to synthesize cDNA. Quantitative detection of mRNA levels of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH), PEPCK, SOAT2, GS and GP genes was performed with an iQ5 optical system (Bio-Rad) with the Power SYBR screen PCR Master Mix (Applied Biosystems) according to the manufacturer's instructions. Primers for real-time RT-PCR for each gene (see Table 1 ) were synthesized by Takara. PCR amplification was carried out in a total volume of 20 μl, containing 1 μl cDNA solution, 10 μl of 2 × Power SYBR Green PCR Master Mix, 1 μl each primer at 10 μM, and 7 μl of nuclease-free water. GAPDH was quantified, and used for the normalization of expression values of the other genes. Fluorescence signals measured during the amplification were considered positive if the fluorescence intensity was more than 20-fold greater than the standard deviation of the baseline fluorescence (Dawson et al., 2005) . The △△CT method of relative quantification was used to determine the fold change in expression (Livak and Schmittgen, 2001 ). Here, the threshold cycle (CT) values of the target mRNAs were first normalized to the CT values of the internal control, GAPDH, in the same samples (△CT= CT target − CT GAPDH ), and then further normalized with the internal control (△△CT= △CT− △CTGAPDH). Fold change in expression was then obtained (2 −△△CT ) as described by Cao et al. (2007) .
Statistical analysis
Results are shown as means ± SEM. Differences between the control and experimental groups were evaluated by one-way analysis of variance (ANOVA). P values less than 0.05 were considered to be statistically significant.
Results
Biochemical parameters
As a first step in characterizing the effect of knocking out an allele of the GCK gene specifically in the liver we compared the fasting blood glucose levels in 2, 4, 16, 24 and 40 week-old liver-specific gck w/-and gck w/w mice. Except at 2-weeks, fasting blood glucose levels at all other ages in the gck w/-mice were significantly higher than those of age-matched gck w/w mice (P b 0.05) (Fig. 1A) . No change in weight was noted between the age-matched gck w/-and gck w/w mice (Fig. 1B) .
The IPGTT displayed a characteristic diabetic curve in gck w/-mice at 16, 26 and 40 weeks of age, where the blood glucose levels at 120 min were significantly higher than those at 0 min, whereas in gck w/w mice, the 120-min glucose levels were not different from the level seen at 0 min (Fig. 1C) . When insulin, TC and TG levels were examined, gck w/-mice showed no significant differences compared to age-matched gck w/w mice (Figs. 2A, B, C). A significant decline in glycogen content was seen at 4 weeks, which was largely recovered at 16 and 26 weeks, but then fell again at 40 weeks (Fig. 2D ). GCK enzyme activity of gck w/-mice was about 50% of that of age-matched GCK w/w mice, except at 2-weeks of age (Fig. 3A) . Levels of GCK protein in gck w/w mice increase starting from 4-weeks of age and become stable from 16-weeks (Figs. 3B, C) while in age-matched gck w/-mice GCK protein levels were significantly lower at 4, 16, 26 and 40 weeks (Figs. 3B, C).
Identification of differentially expressed genes by SSH
A total of 46 cDNA clones were characterized for each of the SSH experiments. Only 10 of the 46 characterized cDNA clones from the 2-week overexpression SSH experiment matched known mouse genes, and resulted in the identification of 6 different genes (Table 2 ). In the 26-week overexpression SSH experiment, 22 of the 46 characterized clones matched known genes, and these clones represented 9 distinct genes (Table 2) . Among the identified genes overexpressed at 26 weeks were the PEPCK and SOAT2, genes that are involved in glucose and lipid metabolism and are highly expressed in the liver. PEPCK is the rate-limiting enzyme of gluconeogenesis and is encoded by the PCK1 gene (Beale et al., 2007) . SOAT2 is an intracellular enzyme present in various eukaryotic cells and catalyzes the formation of cholesterol esters from long-chain fatty acyl coenzyme A and cholesterol (Chang et al., 1997) . Other genes found to be upregulated include FZR1, which is an activator of the anaphase-promoting complex (APC) and ubiquitinates M-phase regulating proteins (Yamamuro et al., 2008) , PCNA, which is a central molecule involved in decisions of life and death of a cell (Paunesku et al., 2001) , Apolipoprotein H, which is involved in inflammatory changes (Niessen et al., 2000) , and CYP, which is the major contributor to oxidative xenobiotic metabolism. Here, in this study, we have focused on the genes that may contribute the metabolic defects thus focused on the PEPCK and SOAT2 genes for further analysis.
Differential expression of metabolic genes
To confirm the differential expression of the PEPCK and SOAT2 genes detected by our SSH screen we performed a quantitative real-time PCR analysis. In addition we also examined the expression of GP and GS, key genes involved in glycogen metabolism. GAPDH was used as an endogenous control for these analyses. PEPCK mRNA levels were significantly increased in the 26-week-old gck w/-mice compared with 2-week-old gck w/-mice, as expected from the SSH result, however no change in the levels of SOAT2 mRNAs was seen between the 26-week-old and 2-week-old gck w/-mice by real-time RT-PCR (Figs. 4A, B) . The expression patterns of PEPCK, SOAT2, GS, and GP were examined with age PEPCK mRNA levels were greater than that found in wild-type mice (Fig. 4A) . At older ages, similar levels of PEPCK mRNA were found in both knockout and wild type mice (Fig. 4A ). GS mRNA levels in gck w/-mice were not different from those of age-matched gck w/w mice, however mRNA levels declined after 4 weeks and then remained low (Fig. 4C) . GP mRNA levels were uniformly low, with no significant difference between gck w/-and gck w/w mice, except at 40 weeks of age where gck w/w mice had significantly higher GP mRNA levels than in age-matched gck w/-mice (Fig. 4D ).
Discussion
In both humans and animal models, specific mutations in the GCK gene cause MODY-2, a disease that is characterized by early onset and persistent hyperglycemia (Froguel et al., 1992; Velho et al., 1992) . GCK plays an essential role in blood glucose homeostasis in both pancreatic beta-cells and the liver. Heterozygous mutations in the GCK gene are a common cause of MODY and a total of 195 different mutations have been reported in subjects of many different racial and ethnic backgrounds (Gloyn, 2003) . The pathophysiological basis of GCKdeficient diabetes is generally viewed as involving both pancreatic (Postic et al., 1999) . In previous studies, the heterozygous GCK knockout mice were hyperglycemic and a global lack of GCK is lethal either at midgestation (Bali et al., 1995) , or a few days after birth (Grupe et al., 1995) . The complete loss of hepatic GCK was not lethal and had only a relatively small effect on the plasma glucose concentration (Postic et al., 1999) . We also generated a liver-specific GCK knockout mouse model for MODY2 using the Cre-loxP gene targeting strategy (Zhang et al., 2004) . A liver-specific GCK knockout mouse should be an ideal animal model to investigate the liver-specific roles of GCK in MODY2. In this study, we focused on the long-term effects of liver-specific GCK depletion and have identified genes that show differential expression in the liver during aging of the liver-specific GCK knockout mice. A diabetic state develops in gck w/-mice by the age of 4 weeks based on the observation of increased fasting blood glucose levels, consistent with our initial characterization of these mice (Zhang et al., 2004) . Fasting blood glucose levels were normal at 2 weeks of age, but increased to more than 9 mmol/l at 4 weeks and remained at this elevated level through 40 weeks of age (Fig. 1A) . Hyperglycemia associated with GCK mutations is often mild, with fewer than 50% of subjects presenting overt diabetes (Froguel and Velho, 1999) . Our gck w/-mice, where GCK is selectively knocked out at one of the two alleles in the liver, yield a GCK expression level that is about 50% of that of wild-type mice, and does not affect GCK expression in pancreatic beta-cells (Zhang et al., 2004) . While blood glucose levels increased, measurement of body weight, serum TC, and TG concentrations showed no difference between gck w/-and gck w/w mice indicating that the liver-specific GCK defect leads to a state of mild diabetes. Whereas chronic hyperglycemia might eventually be expected to lead to an increase in beta cell mass sufficient to match the need for increased insulin production (Bonner-Weir et al., 1989) , this does not seem to be the case which is consistent with previous studies (Postic et al., 1999) . Sustained hyperglycemia has been shown to cause beta-cells to become unresponsive to glucose and the loss of hepatic GCK leads to impaired insulin secretion (Leahy et al., 1992; Rossetti et al., 1990) . Impaired glycogen synthesis and a decreased contribution of the direct pathway of glycogen synthesis have previously been reported in patients with MODY-2 (Rossetti et al., 1990) .
As expected, GCK activity and GCK protein levels were found to be low in 2-week old wild type mice and only increased at 4-weeks of age and remained high beyond that age (Fig. 3) . Previous studies have shown that GCK enzyme activity is absent from livers of rats up to the age of about 16 days when it then begins to gradually rise, and attains a level of about half the adult level at about 24 days and adult levels at about day 30 (Walker and Eaton, 1967; Walker and Holland, 1965) . Like wild type mice, very low levels of GCK activity were seen at 2-weeks in the gck w/-mice (Fig. 3A) . At 4 weeks, and older ages, GCK activity levels were approximately 50% of the levels of age matched wild-type mice (Fig. 3A) , as expected due to the absence of one allele in the knockout mice. The finding that there is no difference of GCK protein levels and enzymatic activity between gck w/w and gck w/-mice at 2 weeks of age likely explains the normal blood glucose levels of gck w/-mice at this age.
Since defects in GCK activity and glycogen storage were seen in our liver-specific gck w/-mice we investigated the effect of long-term GCK deficiency on gene expression in the liver, to identify genes that may contribute to the metabolic defects. We used SSH to enrich for cDNAs from genes that are overexpressed in 26-week old compared to 2-week old gck w/-mice and vice versa. From a total of 46 cDNA clones characterized from each SSH experiment, 6 genes were found to be overexpressed at 2 weeks and 9 genes at 26 weeks (Table 2) . Among the 15 identified upregulated genes, PEPCK and SOAT2 are involved in carbohydrate and lipid metabolism, thus were the best candidates for genes that may partially explain the metabolic defects of the knockout mice. PEPCK is a candidate diabetes and obesity gene (Beale et al., 2004 (Beale et al., , 2007 . The SOAT enzyme participates in various physiological processes such as lipoprotein assembly and dietary cholesterol absorption (Dietschy et al., 1993; Suckling and Stange, 1985; Wilson and Rudel, 1994) , and plays an important role in foam cell development in atherosclerosis (Miyazaki et al., 1998; Tabas, 1995) . Coronary heart disease, though, has a lower prevalence in MODY2 (Velho et al., 1997) .
Real-time RT-PCR was used to confirm the SSH results for the PEPCK and SOAT2 genes and to compare the expression of these genes during aging in both gck w/w and gck w/-mice. Real-time RT-PCR confirmed the overexpression of PEPCK in 26-week old knockout mice (Fig. 4A) . The overexpression of PEPCK was found to be due to the decrease in expression of PEPCK at 2-weeks in gck w/-mice compared to gck w/w mice, rather than due to a change of expression in knockout versus wild-type mice at 26 weeks (Fig. 4A) . During a prolonged fast, when glycogen stores are exhausted, hepatic gluconeogenesis is essential for maintaining glucose homeostasis and the conversion of oxaloacetate to phosphoenolpyruvate (PEP) by PEPCK has long been thought to play a key role in this process (Granner and Pilkis, 1990; Hanson and Reshef, 1997) , PEPCK is highly expressed in the liver, where it is adaptively regulated by a variety of different hormones and other agents in a manner that parallels gluconeogenic flux (Hanson and Garber, 1972; Hanson and Reshef, 1997) . The liver, with depleted glycogen content, has no choice but to enhance gluconeogenesis via PEPCK to produce glucose (Fig. 4A) . In both wild-type (gck w/w ) and GCK knockout (gck w/-) mice, an age-related increase in SOAT2 gene expression was noted, but there was no significant difference in SOAT2 mRNA levels between gck w/-and age-matched gck w/w mice (Fig. 4B) . The similar levels of SOAT2 expression detected by real-time RT-PCR thus may explain why the levels of TC and TG are similar in the two groups of mice (Figs. 2B, C) and the low frequency of coronary heart disease in MODY-2. We also examined by real-time RT-PCR the expression of GP and GS, two enzymes essential for glycogen metabolism, during aging in gck w/-and wild type mice as a defect in glycogen storage were found in 4 and 40 week old gck w/-mice. GP and GS are key rate-limiting enzymes of glycogen metabolism. Low GP expression, or activity, is associated with increased glucose production and decreased glycogen stores due to enhanced gluconeogenesis (Bollen et al., 1998; Gomis et al., 2000) . Glycogen synthesis is the major determinant of non-oxidative glucose metabolism in liver and skeletal muscle, tissues that accumulate glycogen, and plays the most crucial role in maintaining blood glucose homoeostasis. It is generally accepted that GS is the enzyme that controls the rate-limiting step glycogen storage and that GCK is essential for supplying glucose for glycogen synthesis (Bollen et al., 1998; DeFronzo et al., 1982; Ferre et al., 1996) . Differences in GS and GP mRNA levels were not found between gck w/-mice and gck w/w mice (Figs. 4C, D) , despite the glycogen content of gck w/-mice at 4 and 40 weeks being lower than that of age-matched gck w/w mice (Fig. 2D ).
This observation suggests that defect in glucose phosphorylation due to lower GCK activity in 4 week of gck w/-mice leads to loss of glycogen, and not changes in GS. GCK is essential for the synthesis of glycogen via the direct pathway during hyperglycemia, but normal glycogen levels can be maintained as a consequence of an indirect pathway. GP mRNA was found to be depleted in knockout mice, compared to wild-type mice only at 40 weeks of age, which likely is a consequence of the elevation of serum glucose levels and reduction of glycogen store. Abnormalities in liver glycogen metabolism may play an important role in the onset of hyperglycemia in gck w/-mice starting at 4 weeks of age. It is widely recognized that specific mutations in GCK are a major cause of MODY2. Individuals, who are heterozygous for a mutation in the GCK gene exhibit mild fasting or postprandial hyperglycemia (Froguel et al., 1993; Hattersley et al., 1992; Velho et al., 1992 Velho et al., , 1996 accompanied by impaired hepatic glucose uptake and glycogen synthesis, as well as a defect in glucose stimulated insulin secretion. Our liver-specific GCK knockout mouse model shows changes in liver GCK enzymatic activity and is mildly hyperglycemic, but does not have a significant change in insulin secretion. These findings suggest that a disorder of hepatic glucose metabolism, beginning with suppressed glucokinase activity, enhancement of gluconeogenesis and abnormalities in liver glycogen metabolism, are involved in the onset and progression of MODY2. Promoting GCK activity, and protein expression, inhibiting gluconeogenesis and improving glycogen metabolism may help delay and control the onset and progression of MODY2. The liver-specific GCK knockout mouse may also be a powerful model for drug development in the prevention of pathological progression in MODY2.
